

Bayer AG Investor News 2002

As per: November 22, 2002

The latest news which have been published after this day until now, as well as all news contents, can be obtained from our website www.investor.bayer.com

November 22, 2002	Vardenafil Receives Positive Opinion from European Committee for Proprietary Medicinal Products
November 13, 2002	Bayer CropScience to sell additional products to Makhteshim-Agan
November 12, 2002	Q3 2002 Statement
November 11, 2002	Bayer sells household insecticides for EUR 725 million to SC Johnson
October 30, 2002	Bayer Submits Additional New Drug Application For Once-Daily Cipro XR in U.S.
October 28, 2002	Rolf Classon Appointed Chairman of the Board of Management of Bayer HealthCare AG
October 28, 2002	Bayer CropScience AG to sell a range of products to BASF
October 28, 2002	Bayer's Cipro Patent Affirmed by U.S. Courts
October 16, 2002	Bayer and SC Johnson have signed Letter of Intent
October 4, 2002	Bayer plans to sell Rhein Chemie to Advent International
October 2, 2002	Bayer CropScience agrees to products divestments to Makhteshim-Agan
October 01, 2002	Approval of 200 liter fermenters for Kogenate increases production capacity for the U.S.
October 01, 2002	Bayer CropScience becomes first legally independent subgroup
October 01, 2002	Study Comparing Once-Daily Cipro XR to Conventional Twice-Daily Cipro
September 23, 2002	ISSIR Congress: New Vardenafil Data
September 18, 2002	Bayer CropScience agrees to sell wheat herbicide to Arvesta Corporation
September 12, 2002	Bayer cuts a further 4,700 jobs worldwide
August 27, 2002	New Immune Globulin Intravenous Treatment for Approval in Key Global Markets Submitted
August 15, 2002	Pharmaceuticals Division signs declaration of intent to market telmisartan
August 01, 2002	Stockholder's Newsletter 2002: Interim Report for the First Half
July 24, 2002	Bayer agrees to acquire Visible Genetics Inc. for US\$ 61.4 million
July 24, 2002	FDA approvable letter for Vardenafil
July 17, 2002	Bayer plans to sell Haarmann & Reimer to EQT
June 03, 2002	Bayer CropScience ready for launch
May 31, 2002	Bayer to keep fibers business
May 31, 2002	FTC gives the green light for Bayer to acquire Aventis CropScience
May 30, 2002	Bayer sells stake in Agfa-Gevaert
May 22, 2002	Bayer taking additional steps to realign cost base of Pharmaceutical Business

May 21, 2002	New BAY 43-9006 phase I data presented at 2002 ASCO meeting
May 13, 2002	New EUR 170 million TDA plant
May 02, 2002	Avalox i.v. approved in Germany: noticeable drop in treatment costs possible
April 26, 2002	Information for Stockholders 2002: Interim Report for the First Quarter
April 25, 2002	Moxifloxacin IV Reduces Healthcare Costs and Provides Excellent Outcome for Patients hospitalized with Community-Acquired Pneumonia
April 17, 2002	Bayer divests generics business in Spain
April 17, 2002	European Commission clears planned transaction: Bayer can acquire Aventis CropScience
April 15, 2002	New Bayer management team now complete
April 04, 2002	Bayer Pharma France sells generics business to Teva
March 25, 2002	Bayer's euro bonds a resounding success
March 13, 2002	Bayer expects much higher net income in 2002
March 12, 2002	Bayer plans to divest household insecticides
March 08, 2002	Bayer Corporation Submits New Drug Application for Once-Daily Formulation of Ciprofloxacin HCl and Ciprofloxacin
March 07, 2002	Klaus Kühn and Dr. Richard Pott appointed to the Bayer Management Board
March 07, 2002	Bayer to pay dividend of EUR 0.90 per share
March 06, 2002	Active ingredient in Aspirin reduces the risk of myocardial infarction and stroke
February 26, 2002	Patients Reported Vardenafil Significantly Improved Erectile Function Following Radical Prostatectomy
February 20, 2002	Bayer and Aventis Sign Letter of Intent on Joint Venture of Blood Plasma Business
February 05, 2002	Bayer receives offer for generics business in France
January 31, 2002	Bayer and GlaxoSmithKline Announce: EMEA Acceptance of Regulatory Filing for Vardenafil
January 24, 2002	Bayer stock makes its debut on the New York Stock Exchange
January 22, 2002	"New" Bayer Group will be more flexible to boost competitiveness and performance
January 11, 2002	Syngenta and Bayer reach agreement on patent disputes
January 09, 2002	Dr. Wolfgang Plischke appointed new General Manager of the Pharmaceuticals Business Group
January 09, 2002	Bayer and Burrill & Company form diagnostics capital fund